AGI-5198 is primarily used in research settings to study the role of IDH1 mutations in cancer. It is a selective inhibitor of the mutant IDH1 enzyme, which is often found in gliomas and other types of cancer. By inhibiting this enzyme, AGI-5198 reduces the production of the oncometabolite 2-hydroxyglutarate (2-HG), helping researchers understand the metabolic changes and tumor growth mechanisms associated with IDH1 mutations. This compound is particularly valuable in preclinical studies aimed at developing targeted therapies for cancers driven by IDH1 mutations. Its application extends to exploring potential treatments that could disrupt the abnormal metabolic pathways in cancer cells, offering insights into novel therapeutic strategies.